Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | GRK5 | P34947 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | MST1R | Q04912 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17403264 | 0.78 | LTK (0.44) | GSK3AGSK3BALDH1A1RETMET | |
| SCHEMBL28256720 | 0.73 | IDO1 (0.55) | IDO1ALDH1A1MALT1BCHECYP1A2 | |
| SCHEMBL13920074 | 0.71 | PDPK1 (0.42) | GSK3BGFERALDH1A1RPS6KA3L3MBTL1 | |
| SCHEMBL29820079 | 0.70 | LTK (0.43) | GSK3AGSK3BALDH1A1RETMET | |
| SCHEMBL8457758 | 0.69 | IDO1 (0.62) | IDO1ALDH1A1MALT1NPSR1BCHE | |
| SCHEMBL13920149 | 0.68 | NQO2 (0.42) | GSK3AGSK3BGFERALDH1A1BCHE | |
| SCHEMBL17433007 | 0.67 | LTK (0.53) | GSK3AGSK3BALDH1A1RETMET | |
| SCHEMBL3529957 | 0.66 | BRD4 (0.45) | GFERALDH1A1MALT1BCHE | |
| SCHEMBL30206955 | 0.66 | TDP1 (0.55) | IDO1MALT1NPSR1CA12CA1 | |
| SCHEMBL25332560 | 0.66 | L3MBTL1 (0.56) | IDO1ALDH1A1NPSR1CYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827244-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-9827244-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-01-05 | — | — | US | disclosed |
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-01-05 | — | — | US | disclosed |
| US-9359351-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-9359351-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-07 | — | — | US | disclosed |
| WO-2016005330-A1 | DIHYDROPYRIDOPYRAZINE-1,8-DIONES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-14 | — | — | WO | disclosed |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-01-07 | — | — | US | disclosed |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | MME, CAPRIN1, XPNPEP1 | IDO1 2023/4885GSK3A 395/4885GSK3B 304/4885 |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | MME, CAPRIN1, XPNPEP1 | IDO1 2023/4885GSK3A 395/4885GSK3B 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.